Research Topics
Genomes and GenesSpecies | Patrick Y WenSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastomaPatrick Y Wen
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Shields Warren 430 D, Boston, MA 02115, USA
Neuro Oncol 13:437-46. 2011..05- and 1.12-fold, respectively, from baseline during AMG 102 treatment. AMG 102 monotherapy at doses up to 20 mg/kg was not associated with significant antitumor activity in heavily pretreated patients with recurrent GBM...
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomideElizabeth R Gerstner
Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
J Neurooncol 103:325-32. 2011..Vatalanib was well tolerated and this study demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients. Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angiogenic therapies...- Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastomaJan Drappatz
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 78:85-90. 2010..We conducted a Phase I study of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor, in patients with newly diagnosed GBM combined with RT and temozolomide (TMZ)... - Phase II study of protracted daily temozolomide for low-grade gliomas in adultsSantosh Kesari
Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, Boston, MA 02115, USA
Clin Cancer Res 15:330-7. 2009..Protracted treatment with temozolomide potentially overcomes MGMT resistance and improves outcome. We conducted a phase II study of protracted daily temozolomide in adults with low-grade gliomas... - Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)Patrick Y Wen
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney St, Boston, MA 02115, USA
Neuro Oncol 11:853-60. 2009..Single-agent imatinib was well tolerated but had no significant activity in recurrent meningiomas. Trough plasma concentrations of imatinib exceeded those associated with imatinib activity in chronic myelogenous leukemia... - Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adultsSantosh Kesari
Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, 44 Binney St, SW430D, Boston, MA 02115, USA
Neuro Oncol 10:300-8. 2008..07) and PFS (p=0.09). The addition of celecoxib and thalidomide to adjuvant temozolomide was well tolerated but did not meet the primary end point of improvement of 4-month PFS from study enrollment... - Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor
Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
J Clin Oncol 28:2817-23. 2010..Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma... - Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumabEudocia C Quant
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Brigham and Women s Hospital, Boston, MA, USA
Neuro Oncol 11:550-5. 2009..Those patients with malignant gliomas who progressed despite a bevacizumab-containing regimen rarely responded to the second bevacizumab-containing chemotherapeutic regimen. In such patients, alternate therapies should be considered... - An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant gliomaAndrew D Norden
Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
J Neurooncol 92:149-55. 2009..If this conclusion proves correct, progression-free survival may be an inappropriate endpoint for phase II trials of anti-angiogenic therapies... - Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomaAndrew D Norden
Center for Neuro Oncology, Dana Farber Cancer Institute, 44 Binney St SW430B, Boston, MA 02115, USA
J Neurooncol 96:211-7. 2010..The role of EGFR inhibitors in meningiomas is unclear. Evaluation of multi-targeted inhibitors and EGFR inhibitors in combination with other targeted molecular agents may be warranted... 
Medical management of brain tumor patientsJan Drappatz
Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Neurol Clin 25:1035-71, ix. 2007..Effective medical management results in decreased morbidity and mortality and improved quality of life for affected patients...- A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patientsA Gregory Sorensen
A A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA 02114, USA
Cancer Res 69:5296-300. 2009..54; P = 0.004) and progression-free survival (rho = 0.6; P = 0.001). The vascular normalization index described here should be validated in randomized clinical trials... - Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adultsSantosh Kesari
Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Neuro Oncol 9:354-63. 2007..While metronomic chemotherapy may not be useful in patients with advanced disease, further studies using metronomic chemotherapy combined with more potent antiangiogenic agents in patients with less advanced disease may be warranted... - Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranibElizabeth R Gerstner
Departments of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
Neuro Oncol 12:466-72. 2010..ADC maps can be used to suggest regions of infiltrative tumor cells with anti-VEGF therapy and should be validated in future studies... - A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiformeJan Drappatz
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Int J Radiat Oncol Biol Phys 73:222-7. 2009.... - Safety of concurrent bevacizumab therapy and anticoagulation in glioma patientsAndrew D Norden
Center for Neuro Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
J Neurooncol 106:121-5. 2012..03 and 0.02, respectively). Anticoagulant use during BVZ therapy may increase the risk of hemorrhage in glioma patients, although it is generally well tolerated... - Antiangiogenic therapy in malignant gliomasAndrew D Norden
Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Curr Opin Oncol 20:652-61. 2008..This article reviews the rationale for targeting angiogenesis in malignant gliomas, summarizes relevant clinical trial results, and discusses promising avenues of investigation in antiangiogenic therapy... - Antiangiogenic strategies for treatment of malignant gliomasAndrew S Chi
Stephen E and Catherine Pappas Center for Neuro Oncology, Dept of Neurol, Div of Hematol, and Oncol, Massachusetts General Hosp, Cancer Ctr, Boston, MA 02115 Dana Farber Harvard Cancer Ctr, Brigham and Women s Hosp, Boston, MA 02115 Harvard Med School, Brigham and Women s Hosp, Boston, MA 02115, USA
Neurotherapeutics 6:513-26. 2009.... - Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomasRohit R Das
Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
J Neurooncol 107:565-70. 2012..Although clinicians are able to identify patients at high risk for postoperative seizures, treatment with AEDs is ineffective in many patients... - Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathyPaul G Richardson
Dana Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
J Clin Oncol 27:3518-25. 2009..Baseline myeloma-associated neuropathy seems more common than previously reported, and bortezomib-associated neuropathy, although a common toxicity, is reversible in most patients... - Novel anti-angiogenic therapies for malignant gliomasAndrew D Norden
Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
Lancet Neurol 7:1152-60. 2008..Further understanding of the mechanisms of resistance to anti-angiogenic therapies and better selection of patients will be crucial to improve outcomes for patients with malignant glioma... - Morphological characteristics of brain tumors causing seizuresJong Woo Lee
Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
Arch Neurol 67:336-42. 2010..To quantify size and localization differences between tumors presenting with seizures vs nonseizure neurological symptoms... - Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelinePaul G Richardson
Dana Farber Cancer Institute, Boston, MA 02115, USA
Br J Haematol 144:895-903. 2009..Bortezomib-associated peripheral neuropathy is manageable and reversible in most patients with relapsed myeloma. Dose modification using a specific guideline improves peripheral neuropathy management without adversely affecting outcome... - Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomasDeviney Chaponis
Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital Boston, Boston, MA, USA
J Neurooncol 104:179-89. 2011..These data support the continued research of high grade glioma treatment combinations of farnesyl transferase inhibitors, temozolomide, and radiation therapy... - Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escapeEmmanuelle di Tomaso
Department of Radiation Oncology, Massachusetts General Hospital and Massachusetts Institute of Technology, Boston, Massachusetts 02114, USA
Cancer Res 71:19-28. 2011.... - Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomideMichelle L Monje
Department of Neurology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
J Neurooncol 84:179-83. 2007..Radiation-induced high-grade gliomas are a rare but serious late complication of radiotherapy. We report a patient with radiation-induced cerebellar high-grade glioma who had a durable response to temozolomide... - Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progressionElizabeth R Gerstner
Department of Neurology, Division of Neuro Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, 02114 MA, USA
J Neurooncol 94:97-101. 2009..Presence of psPD, independent of treatment, was associated with prolonged progression-free survival (P = 0.05) but not OS. psPD may be more common in combination therapy but most likely by a small margin... - Medical therapies for meningiomasPatrick Y Wen
Center for Neuro Oncology, Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
J Neurooncol 99:365-78. 2010.... - Colon perforation during antiangiogenic therapy for malignant gliomaAndrew D Norden
Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
Neuro Oncol 11:92-5. 2009..Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints... - Longitudinal MRI evidence for decreased survival among periventricular glioblastomaGeoffrey S Young
Department of Radiology, Division of Neuroradiology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
J Neurooncol 104:261-9. 2011..These results suggest that GBMs in close proximity to the ependymal surface of the ventricles convey a worse prognosis-an observation that may be useful for stratifying treatment... - Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatmentPatrick Y Wen
Harvard Medical School, Dana Farber Brigham and Women s Cancer Center, SW430D, Boston, MA 02115, USA
Expert Rev Anticancer Ther 6:733-54. 2006..In this article, the current status of targeted molecular agents for malignant gliomas will be reviewed and strategies to improve their effectiveness will be discussed... - Antiangiogenic therapies for high-grade gliomaAndrew D Norden
Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
Nat Rev Neurol 5:610-20. 2009..The international Response Assessment in Neuro-Oncology Working Group has developed consensus treatment response criteria for HGG that account for the complex effects of antiangiogenic drugs... - Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working groupPatrick Y Wen
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 28:1963-72. 2010..In this proposal, we present the recommendations for updated response criteria for high-grade gliomas... - AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Cancer Cell 11:83-95. 2007..Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor... - Bayesian adaptive randomized trial design for patients with recurrent glioblastomaLorenzo Trippa
Dana Farber Cancer Institute, Harvard School of Public Health and Dana Farber Brigham and Women s Cancer Center, Boston, MA 02215, USA
J Clin Oncol 30:3258-63. 2012..To evaluate whether the use of Bayesian adaptive randomized (AR) designs in clinical trials for glioblastoma is feasible and would allow for more efficient trials... - Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03Eudocia Q Lee
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts 02215, USA
Clin Cancer Res 18:6032-9. 2012..A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG)... - Current clinical development of PI3K pathway inhibitors in glioblastomaPatrick Y Wen
Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
Neuro Oncol 14:819-29. 2012.... - Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trialDavid A Reardon
Center for Neuro Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue SW G460F, Boston, MA 02215, USA
Cancer Chemother Pharmacol 69:849-60. 2012..The primary objective of the study was to determine the maximum tolerated dose (MTD) of ridaforolimus... - Advances in meningioma therapyAndrew D Norden
Center for Neuro Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Curr Neurol Neurosci Rep 9:231-40. 2009..Angiogenesis inhibitors, agents that target fundamental cell signaling pathways, somatostatin analogues, and a variety of other molecular treatments appear promising... - Inhibition of angiogenesis and invasion in malignant gliomasAndrew Chi
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, SW430D, 44 Binney Street, Boston, MA 02115, USA
Expert Rev Anticancer Ther 7:1537-60. 2007..Combination therapy with antiangiogenic and novel anti-invasion agents is a promising approach that may produce a synergistic antitumor effect and a survival benefit for patients with these devastating tumors... - Malignant gliomas in adultsPatrick Y Wen
Division of Neuro-Oncology, Department of Neurology, Dana-Farber[corrected]/Brigham and Women's Hospital, Boston, MA 02115, USA
N Engl J Med 359:492-507. 2008 - Targeted drug therapy for meningiomasAndrew D Norden
Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Neurosurg Focus 23:E12. 2007..Treatment with traditional chemotherapeutic agents has provided minimal benefit. In this review, the role of targeted molecular therapies for recurrent or progressive meningiomas is discussed... - Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02Eudocia Q Lee
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts 02215, USA
Neuro Oncol 14:1511-8. 2012..Minimal activity in recurrent glioblastoma multiforme was seen at the MTD of the 2 combined agents... - Central nervous system complications of cancer therapyMikael L Rinne
Center for Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
J Support Oncol 10:133-41. 2012..This review highlights the CNS complications that result from radiation, chemotherapy, and novel therapeutics... - Survival among patients with primary central nervous system lymphoma, 1973-2004Andrew D Norden
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney St, Boston, MA 02115, USA
J Neurooncol 101:487-93. 2011..55 [95% CI 4.01, 5.16]). Despite treatment advances, survival among PCNSL patients in the United States remains poor. However, in the subset of PCNSL patients who are HIV-negative, survival has improved over time... - Response assessment challenges in clinical trials of gliomasPatrick Y Wen
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center and Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, SW430D, 44 Binney Street, Boston, MA 02115, USA
Curr Oncol Rep 12:68-75. 2010..This review discusses challenges that have emerged in assessing response in patients with gliomas and approaches being introduced to address them... - Treatment of recurrent high-grade gliomasPatrick Y Wen
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts 02115, USA
Curr Opin Neurol 22:657-64. 2009..Although therapies for patients with recurrent high-grade gliomas are limited, there has been important progress recently. This review summarizes current treatments for recurrent high-grade gliomas with an emphasis on more novel approaches... - Response assessment in neuro-oncologyEudocia C Quant
Center for Neuro Oncology, Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney Street, Boston, MA 02115, USA
Curr Oncol Rep 13:50-6. 2011..This article reviews current response criteria for high-grade glioma, low-grade glioma, brain metastasis, meningioma, and schwannoma... - Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectivesDavid P Samuel
Harvard Medical School, Pediatric Medical Neuro Oncology, Dana Farber Cancer Institute and Children s Hospital of Boston, Boston, MA 02115, USA
Expert Opin Investig Drugs 18:973-83. 2009.... - Cerebrospinal fluid spread of anaplastic gliomaOzden Narin
Dana-Farber/Brigham and Women's Cancer Center, Center for Neuro-Oncology, Boston, MA, USA
J Clin Oncol 25:596-7. 2007 - Targeted molecular therapy of malignant gliomasSantosh Kesari
Center for Neuro-Oncology, Dana Farber/Brigham and Women's Cancer Center, Boston, MA 02115, USA
Curr Neurol Neurosci Rep 5:186-97. 2005..This review summarizes the current results with targeted molecular agents in malignant gliomas and strategies under evaluation to increase their effectiveness... - Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08Patrick Y Wen
Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
Clin Cancer Res 12:4899-907. 2006..Phase II: To determine the therapeutic efficacy of imatinib... - Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinibDavid M Jackman
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 24:4517-20. 2006 - Glioma therapy in adultsAndrew D Norden
Division of Cancer Neurology, Department of Neurology, Brigham and Women's Hospital and Center For Neuro-Oncology, Dana Farber Brigham and Women's Cancer Center, Boston, Massachusetts 02115, USA
Neurologist 12:279-92. 2006..Rapid progress in the field of glioma molecular biology continues to identify therapeutic targets and provide hope for the future of this challenging disease... - Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 casesSantosh Kesari
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
J Neurooncol 88:175-83. 2008..We retrospectively evaluated the clinical, radiographic, histologic, and treatment features from 101 adults with presumed or biopsy proven BSG to determine prognostic factors... - Therapeutic strategies for inhibiting invasion in glioblastomaJan Drappatz
Center for Neuro Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston MA 02115, USA
Expert Rev Neurother 9:519-34. 2009..Recently, there has been important progress in understanding the molecular determinants of glioma invasion and migration. This review will summarize some of the therapeutic strategies for inhibiting invasion in glioblastomas... - Response criteria for gliomaA Gregory Sorensen
Harvard Medical School, Boston, MA, USA
Nat Clin Pract Oncol 5:634-44. 2008.... - Recurrent acute promyelocytic leukemia presenting as a sacral nerve root massSantosh Kesari
Department of Neurology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA, USA
J Clin Oncol 26:3279-81. 2008 - Prospective, high-throughput molecular profiling of human gliomasAndrew S Chi
Department of Neurology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
J Neurooncol 110:89-98. 2012.... - Discontinuing bevacizumab in patients with glioblastoma: an ethical analysisJennifer C Kesselheim
Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
Oncologist 16:1435-9. 2011..With the increasing availability of new, modestly toxic, expensive drugs for patients with advanced cancer, questions of when to stop these drugs will become increasingly relevant... - Epidemiology of brain metastasesLakshmi Nayak
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 450 Brookline Avenue, SW 430D, Boston, MA 02215, USA
Curr Oncol Rep 14:48-54. 2012..Some patients present with no known primary cancer diagnosis. In children, brain metastases are rare; germ cell tumors, sarcomas, and neuroblastoma are the common offenders... - Therapy for recurrent malignant glioma in adultsMaciej M Mrugala
Harvard Medical School, Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02114, USA
Expert Rev Anticancer Ther 4:759-82. 2004..Standard therapy for patients with this disease will be reviewed, together with more novel approaches such as targeted molecular therapies, angiogenesis inhibitors, immunotherapies, gene therapies and intratumoral therapies... - Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trialsEudocia C Quant
Division of Cancer Neurology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, SW 430D, Boston, MA 02115, USA
Neuroimaging Clin N Am 20:425-48. 2010..This article reviews novel therapies for glioblastoma, with an emphasis on targeted agents... - Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q lossMatija Snuderl
Pathology Service, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 2698, USA
Clin Cancer Res 15:6430-7. 2009..The purpose of this study was to evaluate the prognostic significance of polysomy of chromosomes 1 and 19 in the setting of 1p/19q codeletion... - Medical management of patients with brain tumorsPatrick Y Wen
Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital and Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney Street, Boston, MA 02115, USA
J Neurooncol 80:313-32. 2006..Medications such as modafinil and methylphenidate have assumed an increasing role in the treatment of fatigue, while donepezil and memantine may be helpful with memory loss... - Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomibPaul G Richardson
Dana Farber Cancer Institute, Brigham and Women s Hospital, 44 Binney St, Dana 1B02, Boston, MA 02115, USA
J Clin Oncol 24:3113-20. 2006..To determine the frequency, characteristics, and reversibility of peripheral neuropathy from bortezomib treatment of advanced multiple myeloma... - Non-cytotoxic drugs as potential treatments for gliomasJan Drappatz
Center for Neuro-Oncology, Dana Farber Cancer Institute, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
Curr Opin Neurol 17:663-73. 2004..As we learn to use these agents more effectively, and as an increasing number of new and potentially promising agents are developed, it is likely that therapies for malignant gliomas will improve over the next few years... - Brain metastasesAndrew D Norden
Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA
Curr Opin Neurol 18:654-61. 2005..The potentially substantial role for chemotherapeutics that cross the blood-brain barrier and for novel targeted molecular agents is now being elucidated... - Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomasGaurav D Shah
Brigham and Women's Hospital, Boston, MA 02115, USA
Neuro Oncol 8:38-46. 2006..Thus, linear methods are comparable to volumetric methods, but simpler to implement for routine clinical use and for designing clinical trials of brain tumors... - Emerging antiangiogenic treatments for gliomas - efficacy and safety issuesJörg Dietrich
Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Curr Opin Neurol 21:736-44. 2008..To review the rationale and recent experience of angiogenesis inhibitors in malignant gliomas and to highlight both the promise and potential complications of these agents... - Recurrent high-grade gliomaEudocia C Quant
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430B, 44 Binney Street, Boston, MA, 02115, USA
Curr Treat Options Neurol 12:321-33. 2010.... - Chemotherapy and targeted molecular therapies for brain metastasesJan Drappatz
Center for Neuro Oncology Dana Farber Brigham and Women s Cancer Center, and Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
Expert Rev Neurother 6:1465-79. 2006..In this review, the current role of chemotherapy and targeted molecular agents for brain metastases is summarized and future directions are discussed... - Inhibiting kinases in malignant gliomasAndrew S Chi
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Shields Warren 430D, 44 Binney Street, Boston, MA 02115, USA
Expert Opin Ther Targets 11:473-96. 2007..This article reviews the important protein kinases in malignant gliomas, summarizes the existing clinical development of kinase inhibitors and discusses strategies to improve their effectiveness... - Malignant gliomasPatrick Y Wen
Center for Neuro Oncology, Dana Farber Cancer Institute, SW430D, 44 Binney Street, Boston, MA 02115, USA
Curr Neurol Neurosci Rep 4:218-27. 2004..Although therapy for patients with these tumors remains limited, there has been important progress recently. In this review, some of these advances are discussed, with an emphasis on targeted molecular therapies... - Medical management of patients with brain tumorsPatrick Y Wen
Harvard Medical School, Center for Neuro Oncolgy, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Curr Opin Oncol 14:299-307. 2002.... - Neurologic complications of cancer therapyScott R Plotkin
Department of Neurology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02446, USA
Neurol Clin 21:279-318, x. 2003.... - Neurologic complications of solid tumorsPatrick Y Wen
Division of Neuro Oncology, Department of Neurology, Brigham and Women s Hospital, 75 Francis St Boston, MA 02115, USA
Neurol Clin 21:107-40, viii. 2003..As systemic therapy improves for many of these tumors, patients are surviving longer and the incidence of neurologic complications is increasing... - Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entitiesElizabeth A Maher
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Cancer Res 66:11502-13. 2006..We conclude that glioblastoma is composed of at least three distinct molecular subtypes, including novel subgroups of secondary glioblastoma, which may benefit from different therapeutic strategies...